- Home
- GLUE
as 02-21-2025 4:00pm EST
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 407.3M | IPO Year: | 2021 |
| Target Price: | $12.67 | AVG Volume (30 days): | 512.9K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $12.40 | Next Earning Date: | 03-13-2025 |
| Revenue: | $14,975,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -40.56% |
Latest Monte Rosa Therapeutics Inc. News
GLUE Breaking Stock News: Dive into GLUE Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans
TipRanks
a month ago
Monte Rosa Therapeutics provide corporate update, key milestones 2025
GlobeNewswire
a month ago
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
GlobeNewswire
2 months ago
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
2 months ago
Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14
GlobeNewswire
2 months ago
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
MT Newswires
2 months ago
Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression
MT Newswires
2 months ago
Monte Rosa Closes Global License Agreement With Novartis
Compare GLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.